Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27819435 | 0.97 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL216634 | 0.83 | APP (0.46) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL15203858 | 0.82 | PTGS1 (0.41) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL4455275 | 0.81 | APP (0.44) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL19811951 | 0.81 | APP (0.44) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL778506 | 0.81 | APP (0.44) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Pyridine SCHEMBL29217360 | 0.81 | PTGS1 (0.38) | PTGS1TSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL19811888 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL4759462 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL19811047 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143638-A | Preparation method of 2-adamantanoic acid-trifluoropropane sulfonic acid-derived high-purity electronic grade photoinduced acid generator | 苏州威迈芯材半导体有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240384065-A1 | SILOXANE RESIN COMPOSITION FOR FORMING CURED FILM, CURED FILM, AND METHOD OF PRODUCING POLYSILOXANE | TORAY INDUSTRIES, INC. (JP) | 2024-11-21 | — | — | US | claimed |
| WO-2024185458-A1 | RESIN COMPOSITION, CURED FILM, METHOD FOR PRODUCING SUBSTRATE WITH PATTERN OF CURED FILM, OPTICAL ELEMENT, AND METHOD FOR PRODUCING POLYSILOXANE | 東レ株式会社 | 2024-09-12 | — | — | WO | claimed |
| CN-117858927-A | Silicone resin composition for forming cured film, and method for producing polysiloxane | 东丽株式会社 | 2024-04-09 | — | — | CN | claimed |
| WO-2023048062-A1 | SILOXANE RESIN COMPOSITION FOR FORMING CURED FILM, CURED FILM, AND METHOD FOR PRODUCING POLYSILOXANE | 東レ株式会社 | 2023-03-30 | — | — | WO | claimed |
| CN-113871720-A | High-safety electrolyte and preparation method and application thereof | 厦门大学 | 2021-12-31 | — | — | CN | claimed |
| CN-110556509-A | Method for performing surface protection and passivation treatment on metallic lithium cathode by using fluorine-containing organic matter, product and application | NANJING UNIVERSITY OF TECHNOLOGY | 2019-12-10 | — | — | CN | claimed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | claimed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | claimed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | claimed |
| JP-3940358-B2 | — | — | 2007-07-04 | — | — | JP | claimed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | claimed |
| US-6992199-B2 | Method for sulphonylating a hydroxylated organic compound | RHODIA CHIMIE (FR) | 2006-01-31 | — | — | US | claimed |
| EP-1322601-B1 | METHOD FOR SULPHONYLATING A HYDROXYLATED ORGANIC COMPOUND | RHODIA CHIMIE SA (FR) | 2005-08-03 | — | — | EP | claimed |
| JP-2004510760-A | — | — | 2004-04-08 | — | — | JP | claimed |
| JP-3501455-B2 | — | — | 2004-03-02 | — | — | JP | claimed |
| US-20040024257-A1 | Method for sulphonylating a hydroxylated organic compound | CHIMIE, RHODIA (FR) | 2004-02-05 | — | — | US | claimed |
| EP-1322601-A1 | METHOD FOR SULPHONYLATING A HYDROXYLATED ORGANIC COMPOUND | Rhodia Chimie (FR) | 2003-07-02 | — | — | EP | claimed |
| WO-2002028826-A1 | METHOD FOR SULPHONYLATING A HYDROXYLATED ORGANIC COMPOUND | RHODIA CHIMIE (FR) | 2002-04-11 | — | — | WO | claimed |
| WO-1993003113-A1 | LIQUID-CRYSTAL COMPOUNDS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1993-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | PTGS1 1627/4885PDE4A 2724/4885LMNA 1855/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | PTGS1 1627/4885PDE4A 2724/4885LMNA 1855/4885 |
| US-20040024257-A1 | Method for sulphonylating a hydroxylated organic compound | TST, SCLY, SDHB | PTGS1 3606/4885PDE4A 4832/4885LMNA 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.